



























































































































































































14. Steinhubl SR, **Moliterno DJ**. Antiplatelet and anticoagulant therapy in the prevention of ischemic heart disease. In "Preventative Cardiology" edited by Robinson R; Futura Publishing Co. Inc., Armonk, NY, 1998, pp 355-382.
15. **Moliterno DJ**. Anticoagulants in the treatment of acute coronary syndromes. In "Textbook of Interventional Cardiology" 3<sup>rd</sup> ed. edited by Topol EJ; W.B. Saunders Co., Philadelphia, 1999, pp 25-51.
16. **Moliterno DJ**, White HD. Unstable angina: PARAGON, PURSUIT, PRISM, and PRISM-PLUS. In "Contemporary Cardiology: Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease" edited by Lincoff AM, Topol EJ. Humana Press, Inc., Totowa, New Jersey 1999, pp 201-227.
17. Granger CJ, **Moliterno DJ**. Bedside anticoagulant testing. In "Acute Coronary Syndromes" 2<sup>nd</sup> ed. edited by Topol EJ; Marcel Dekker, New York, 2000, pp 541-562.
18. Kapadia SR, **Moliterno DJ**. Section II editors: Chronic ischemic syndromes. In "Manual of Cardiovascular Medicine" edited by Marso SP, Griffin BP, Topol EJ; Lippincott Williams & Wilkins, New York, 2000, pp 69-96.
19. **Moliterno DJ**. Anticoagulants. In "CathSAP II" edited by Nissen SE; American College of Cardiology; Bethesda, 2000, pp 23-30.
20. **Moliterno DJ**. Care after myocardial infarction. Section in "Conn's Current Therapy 2000" edited by RE Rakel; W.B. Saunders Co., Philadelphia, 2000, pp 328-333.
21. **Moliterno DJ**, Granger CB. Differences between unstable angina and myocardial infarction: The Pathophysiologic and Clinical Spectrum. In "Acute Coronary Syndromes" 2<sup>nd</sup> ed. edited by Topol EJ; Marcel Dekker, New York, NY, 2000, pp 135-172.
22. Mukherjee DB, **Moliterno DJ**. Bedside platelet monitoring. In "Acute Coronary Syndromes" 2<sup>nd</sup> ed. edited by Topol EJ; Marcel Dekker, New York, 2000, pp 563-597.
23. Chan AW, **Moliterno DJ**. Restenosis: the clinical issues. In "Textbook of Interventional Cardiology" 4<sup>th</sup> ed. edited by Topol EJ; W.B. Saunders Co., Philadelphia, 2002, pp 415-453.
24. **Moliterno DJ**, Topol EJ. Restenosis: epidemiology and treatment. In "Textbook of Cardiovascular Medicine" 2<sup>nd</sup> ed. edited by Topol EJ; Williams & Wilkins Publishers, Philadelphia, 2002, pp 1715-1750.
25. **Moliterno DJ**. Anticoagulants and their use in acute coronary syndromes and coronary interventions. In "Textbook of Interventional Cardiology" 4<sup>th</sup> ed. edited by Topol EJ; W.B. Saunders Co., Philadelphia, 2003, pp 33-64.
26. **Moliterno DJ**. Unstable angina: PARAGON, PURSUIT, PRISM, and PRISM-PLUS. In "Contemporary Cardiology: Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease" 2<sup>nd</sup> ed. edited by Lincoff AM, Topol EJ. Humana Press Inc., Totowa, NJ, 2003, pp 233-262.
27. Chan AW, **Moliterno DJ**. Clinical evaluation of restenosis. In "Atherothrombosis and Coronary Artery Disease" 2<sup>nd</sup> ed. edited Fuster V, Topol EJ, Nabel EG; Raven Press, New York, 2004.

28. Quinn MJ, **Moliterno DJ**. Anticoagulation trials in acute coronary syndromes. In “A Comprehensive Handheld-Based Approach to CardioVascular Medicine” edited by Roffi M, Meier B, Topol, EJ; CVMstat<sup>®</sup>, Handheldmed, Inc., Little Rock, AR, 2004.
29. Mukherjee D, **Moliterno DJ**. Bedside platelet monitoring. In “Acute Coronary Syndromes” 3<sup>rd</sup> ed. edited by Topol EJ; Marcel Dekker, New York, 2005, pp 481-506.
30. Mukherjee D, **Moliterno DJ**. Monitoring anticoagulants in the catheterization laboratory and in the ICU when using combination therapies. In “Clinical, Interventional, and Investigational Thrombocardiology (Fundamental and Clinical Cardiology)” edited by Becker RC, Harrington RA, Marcel Dekker Publications, 2005.
31. Saw J, **Moliterno DJ**. Antiplatelet agents. In “Platelet Function: Assessment, Diagnosis and Treatment” edited by Quinn MJ, Fitzgerald D; Humana Press, Inc., Totowa, NJ, 2005, pp 335-367.
32. Saw J, **Moliterno DJ**. Bedside anticoagulant testing. In “Acute Coronary Syndromes” 3<sup>rd</sup> ed. edited by Topol EJ; Marcel Dekker, New York, 2005, pp 457-480.
33. Saw J, **Moliterno DJ**. Differences between unstable angina and acute myocardial infarction: pathophysiologic and clinical spectrum. In “Acute Coronary Syndromes” 3<sup>rd</sup> ed. edited by Topol EJ; Marcel Dekker, New York, 2005, pp 129-156.
34. Saw J, **Moliterno DJ**. The rebirth of interest in pharmacoinvasive therapy in the stent era. In “Pharmacoinvasive Therapy in Acute Myocardial Infarction” edited by Sobel B, Dauerman H; Taylor & Francis, New York, 2005, pp 131-148.
35. Brown B, **Moliterno DJ**. Glycoprotein IIb/IIIa inhibitors – status 2005. In “Therapeutic Strategies in Thrombosis” edited by Kristensen SD, De Caterina R, **Moliterno DJ**; Clinical Publishing, Oxford, 2006, pp 37-60.
36. Hamdalla H, **Moliterno DJ**. Procedures and management: multivessel angioplasty. Chapter 14 in “SCAI Interventional Cardiology Board Review Book” edited by Kern M, et al. Lippincott Williams & Wilkins, 2006, pp 147-156.
37. Marshall JJ, **Moliterno DJ**. Pharmacology and ionotropes, antiarrhythmics, sedatives, and lipid-lowering agents. Chapter 6 in “900 Questions: An Interventional Cardiology Board Review” edited by Mukherjee D, Cho L, **Moliterno DJ**; Lippincott Williams & Wilkins, 2006, pp 41-48.
38. **Moliterno DJ**. Antiplatelet, antithrombotic, and thrombolytic agents. Chapter 5 in “900 Questions: An Interventional Cardiology Board Review” edited by Mukherjee D, Cho L, **Moliterno DJ**; Lippincott Williams & Wilkins, 2006, pp 32-40.
39. **Moliterno DJ**, Cho L, Mukherjee D. Primary, rescue, and facilitated angioplasty. Chapter 11 in “900 Questions: An Interventional Cardiology Board Review” edited by Mukherjee D, Cho L, **Moliterno DJ**; Lippincott Williams & Wilkins, Philadelphia, 2006, pp 88-96.
40. Morrison DA, **Moliterno DJ**, Vetrovec GW. Approach to coronary artery disease: medical therapy (including risk-factor modification), coronary artery bypass graft surgery, and percutaneous coronary intervention including complex PCI. Chapter 19 in “SCAI Interventional Cardiology Board Review Book” edited by Kern M, et al. Lippincott Williams & Wilkins, 2006, pp 189-201.

41. Saraff K, Mukherjee D, **Moliterno DJ**. Monitoring of antithrombotic drugs. In “Therapeutic Strategies in Thrombosis” edited by Kristensen SD, et al. Clinical Publishing, Oxford, 2006, pp 359-383.
42. **Moliterno DJ**. Thrombosis. Chapter 24 in “ACCSAP-6” (Adult Clinical Cardiology Self-Assessment Program) edited by Lewis RP, co-edited by O’Gara P, Friesinger II GC, Hirsch GA; American College of Cardiology, 2007. [www.cardiosource.com](http://www.cardiosource.com)
43. Bhatheja R, **Moliterno DJ**. The interrelationship of thrombin and platelets—the protease-activated Receptor-1. Chapter 30 in “New Therapeutic Agents in Thrombosis and Thrombolysis” edited by Freedman JE, Loscalzo J; Informa Healthcare, USA, 2008, pp 517-533.
44. Falluji N, **Moliterno DJ**. Restenosis and in-stent restenosis. In “Essential Interventional Cardiology” 2<sup>nd</sup> ed. edited by Norell MS, Perrins EJ, Meier B, Lincoff AM; Saunders, Philadelphia, 2008, pp 151-161.
45. Hamdalla H, **Moliterno DJ**. Multivessel coronary artery disease. Chapter 9.5 in “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, 2008.
46. Jozic J, **Moliterno DJ**. Platelet glycoprotein IIb/IIIa receptor antagonists: fundamental and pharmacological aspects. Chapter 12 in “Clinical Guide to the Use of Antithrombotic Drugs in Coronary Artery Disease” edited by Angiolillo DJ, Kastrati A, Simon DI; Informa Healthcare, USA, 2008, pp 101-105.
47. Macaulay T, **Moliterno DJ**. Vasopressors, ionotropes, and vasodilators. Chapter 6.8 in “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, 2008.
48. **Moliterno DJ**. Platelet glycoprotein IIb/IIIa inhibitors. Chapter 6.2 in “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, 2008.
49. **Moliterno DJ**. Restenosis. Chapter 2.6 in “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, 2008.
50. Mukherjee D, **Moliterno DJ**. Chronic total Occlusions. Chapter 9.1 in “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, 2008.
51. Mukherjee D, **Moliterno DJ**. Heparin-induced thrombocytopenia. Chapter 2.5 in “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, 2008.

52. Mukherjee D, **Moliterno DJ**. Hypercoaguable disorders. Chapter 2.4 in “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, 2008.
53. Dawson CB, Mukherjee D, **Moliterno DJ**. High dose tirofiban. Chapter 19 in “Pharmacology in the Catheterization Laboratory” edited by Waksman R, Ajani A; Blackwell Publishing, Oxford, 2009, pp 154-157.
54. Falluji N, **Moliterno DJ**, Mukherjee D. Rescue coronary intervention for failed thrombolysis. Chapter 7 in “Primary Angioplasty in Acute Myocardial Infarction” edited by Tcheng, JE; Humana Press, Inc., Totowa, New Jersey, 2009, pp 101-114.
55. Dosh KM, **Moliterno DJ**. Glycoprotein IIb/IIIa Inhibitors. Chapter 8 in “Mechanical Reperfusion for STEMI: From Randomized Trial to Clinical Practice” edited by DeLuca G, Lansky A; Informa Healthcare USA, New York, New York, 2009, pp 83-93.
56. Macaulay TE, **Moliterno DJ**. Vasopressors, vasodilators, and antithrombotics in the catheterization laboratory. Chapter 7 in “Cardiovascular Catheterization and Intervention: A Textbook of Coronary, Peripheral and Structural Heart Disease” edited by Mukherjee D, Bates E, Roffi M, **Moliterno DJ**; Informa Healthcare, London, 2010, pp 53-66.
57. Gurley J, **Moliterno DJ**. Radiation Safety, Equipment, and Basic Concepts. Chapter 3 in “Interventional Cardiology 1001 Questions: An Interventional Cardiology Board Review” edited by Mukherjee D, Cho L, **Moliterno DJ**; Lippincott Williams & Wilkins, Baltimore, MD, 2012, pp 23-37.
58. **Moliterno DJ**, Macaulay TE. Antiplatelet, Antithrombotic, and Thrombolytic Agents. Chapter 5 in “Interventional Cardiology 1001 Questions: An Interventional Cardiology Board Review” edited by Mukherjee D, Cho L, **Moliterno DJ**; Lippincott Williams & Wilkins, Baltimore, MD, 2012, pp 50-59.
59. Dunn SP, **Moliterno DJ**. Antiarrhythmics, Sedatives, and Lipid-lowering Agents. Chapter 7 in “Interventional Cardiology 1001 Questions: An Interventional Cardiology Board Review” edited by Mukherjee D, Cho L, **Moliterno DJ**; Lippincott Williams & Wilkins, Baltimore, MD, 2012, pp 69-76.
60. Macaulay TE, Moliterno DJ. Iotropes, Vasopressors, and Vasodilators. Chapter 8 in “Interventional Cardiology 1001 Questions: An Interventional Cardiology Board Review” edited by Mukherjee D, Cho L, Moliterno DJ; Lippincott Williams & Wilkins, Baltimore, MD, 2012, pp 77-84.
61. Foley JD 3rd, **Moliterno DJ**. Platelet ADP P2Y12 Inhibitors: Thienopyridines, Chapter 3 in “Therapeutic Advances in Thrombosis, 2nd edition” edited by **Moliterno DJ**, Kristensen SD, De Caterina R, Wiley-Blackwell, London, 2012, pp 26-46.
62. Foley JD 3rd, **Moliterno DJ**. Platelet ADP P2Y12 Inhibitors: Nonthienopyridines, Chapter 4 in 7 “Therapeutic Advances in Thrombosis, 2nd edition.” edited by **Moliterno DJ**, Kristensen SD, De Caterina R, Wiley-Blackwell, London, 2012, pp 47-61.

63. Wiisanen ME, **Moliterno DJ**. Interrelationship of Thrombin and Platelets: The Protease Activated Receptor-1. Chapter 7 in “Therapeutic Advances in Thrombosis, 2nd edition.” edited by **Moliterno DJ**, Kristensen SD, De Caterina R, Wiley-Blackwell, London, 2012, pp 71-86.
64. **Moliterno DJ**. Hemostasis, Platelet Biology, and the Coagulation Cascade. Chapter 1.3 in “CathSAP-4” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation, 2012
65. Anaya P, **Moliterno DJ**. Hypercoaguable Disorders. Chapter 2.4 in “CathSAP-4” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation, 2012
66. **Moliterno DJ**. Heparin-Induced Thrombocytopenia. Chapter 6.6 in “CathSAP-4” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation, 2012
67. Macaulay TE, **Moliterno DJ**. Vasopressors, vasodilators, and antithrombotics in the catheterization laboratory. Chapter 7 in “Cardiovascular Catheterization and Intervention: A Textbook of Coronary, Peripheral and Structural Heart Disease” edited by Mukherjee D, Bates E, Roffi M, Lange RA, **Moliterno DJ**; Informa Healthcare, London, 2018, pp 71-88.
68. **Moliterno DJ**, Macaulay TE. Antiplatelet, Antithrombotic, and Thrombolytic Agents. Chapter 5 in “Interventional Cardiology 1133 Questions: An Interventional Cardiology Board Review, 3<sup>rd</sup> Edition” edited by Mukherjee D, Lange RA, Chatterjee S, Cho L, **Moliterno DJ**. Wolters Kluwer, New York, 2019, pp 23-36.
69. Dunn SP, **Moliterno DJ**. Antiarrhythmics, Sedatives, and Lipid-lowering Agents. Chapter 7 in “Interventional Cardiology 1133 Questions: An Interventional Cardiology Board Review, 3<sup>rd</sup> Edition” edited by Mukherjee D, Lange RA, Chatterjee S, Cho L, **Moliterno DJ**. Wolters Kluwer, New York, 2019, pp 68-75.
70. Macaulay TE, Moliterno DJ. Inotropes, Vasopressors, and Vasodilators. Chapter 8 in “Interventional Cardiology 1133 Questions: An Interventional Cardiology Board Review, 3<sup>rd</sup> Edition” edited by Mukherjee D, Lange RA, Chatterjee S, Cho L, **Moliterno DJ**. Wolters Kluwer, New York, 2019, pp 76-83.



